October 01, 2013
1 min read
Save

Cancer center fills leadership posts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Memorial Sloan-Kettering Cancer Center recently announced two leadership appointments.

David R. Jones, MD, has been named chief of the Thoracic Service in the department of surgery, and Charles M. Rudin, MD, PhD, has been named chief of the Thoracic Oncology Service in the division of solid tumor oncology within the department of medicine.

“Drs. Jones and Rudin are internationally recognized leaders in their respective fields,” José Baselga, MD, physician-in-chief at Memorial Hospital, said in a press release. “They will collaborate to lead a multidisciplinary program combining modern genomic characterization of thoracic cancers, the latest innovations in minimally invasive surgery, and advances in medical therapy to ensure that our patients receive the very best in cancer care. Their expertise as clinicians and their strong record of accomplishments in clinical and translational research make them ideal leaders of MSKCC’s Thoracic Service and Thoracic Oncology Service.”

David R. Jones, MD 

David R. Jones

Charles M. Rudin, MD, PhD 

Charles M. Rudin

Jones, a thoracic surgeon, previously served as vice chair of surgery and chief of thoracic and cardiovascular surgery at the University of Virginia. He is a permanent member of the NIH/NCI Tumor Progression and Metastasis Study Section and an active participant in the NCI’s Cancer Genome Atlas Project.

Rudin, a medical oncologist and translational researcher, previously served as director of lung cancer therapeutics and associate director for clinical research at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. He has conducted preclinical studies using patient-derived tumor tissue for preclinical drug testing of new therapies in lung cancer. He also has led comprehensive analysis of the genomic alterations in small cell lung cancer.